Literature DB >> 2973643

Energy metabolism in disorders of the nervous system.

J P Blass1, R K Sheu, J M Cedarbaum.   

Abstract

"Energy metabolism" is deranged in a wide variety of disorders of the nervous system. This term refers rather loosely to the pathways responsible for the utilization of the major substrates of brain. Primary disorders of energy metabolism are those in which the primary insult affects the cellular machinery required for energy metabolism. A typical example would be a defect in a gene coding for a mitochondrial protein. Biochemically, defects which appear to be hereditary and which lead to disease of the central nervous system have been described in each of the pathways of energy metabolism: glycogenolysis (the break-down of glycogen to glucose); glycolysis (the break down of glucose to pyruvate and lactate); the pyruvate dehydrogenase complex (which oxidizes pyruvate to enter the Krebs tricarboxylic acid cycle); the tricarboxylic acid cycle itself (which completes the oxidation of carbohydrates and other substrates to carbon dioxide); electron transport (which carries out their oxidation to water); the pentose phosphate pathway (an alternate pathway for glucose oxidation); and several "minor" mitochondrial pathways. Clinically, the spectrum of syndromes associated with primary disorders of energy metabolism is wide. Common manifestations include psychomotor retardation, with associated lactic acidosis and/or hypoglycemia. The laboratory abnormalities may be intermittent. Syndromes which have been culled out include congenital lactic acidosis, Leigh disease, intermittent ataxia, Kearns-Sayre-Shy syndrome (KSS), myoclonus epilepsy with ragged red fibers (MERRF), and mitochondrial myopathy-encephalopathy-lactic acidosis-stroke (MELAS). As with other families of inborn errors, both clinical and biochemical heterogeneity occur. Patients with apparently similar clinical syndromes can turn out to have different inborn errors, and patients with abnormalities of the same gene product can have clinically distinguishable syndromes. Secondary disorders are those in which the derangements of energy metabolism are presumably secondary to some other insult but may still be important for the cellular pathophysiology. These include the metabolic encephalopathies and probably a number of well-known neurodegenerative disorders. In the hereditary ataxias, abnormalities of mitochondrial markers are common but do not correlate consistently with the disorders as conventionally classified; a new classification into axonal ataxias, multiple system degenerations, and ataxic encephalopathies may be easier to relate to the pathophysiology.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2973643

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  13 in total

1.  Transcriptome profile in Williams-Beuren syndrome lymphoblast cells reveals gene pathways implicated in glucose intolerance and visuospatial construction deficits.

Authors:  Anna Antonell; Mireia Vilardell; Luis A Pérez Jurado
Journal:  Hum Genet       Date:  2010-04-17       Impact factor: 4.132

2.  Differentiated effect of ageing on the enzymes of Krebs' cycle, electron transfer complexes and glutamate metabolism of non-synaptic and intra-synaptic mitochondria from cerebral cortex.

Authors:  R F Villa; A Gorini; S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  2006-09-14       Impact factor: 3.575

3.  Regulation of neuronal bioenergy homeostasis by glutamate.

Authors:  Katrina Foo; Laura Blumenthal; Heng-Ye Man
Journal:  Neurochem Int       Date:  2012-06-16       Impact factor: 3.921

Review 4.  Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders.

Authors:  Isidro Salcedo; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 5.  In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models.

Authors:  In-Young Choi; Sang-Pil Lee; David N Guilfoyle; Joseph A Helpern
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

6.  Regional brain effects of sodium azide treatment on cytochrome oxidase activity: a quantitative histochemical study.

Authors:  A Cada; F Gonzalez-Lima; G M Rose; M C Bennett
Journal:  Metab Brain Dis       Date:  1995-12       Impact factor: 3.584

7.  Confirmation of the SCA-2 locus as an alternative locus for dominantly inherited spinocerebellar ataxias and refinement of the candidate region.

Authors:  I Lopes-Cendes; E Andermann; E Attig; F Cendes; S Bosch; M Wagner; F Gerstenbrand; F Andermann; G A Rouleau
Journal:  Am J Hum Genet       Date:  1994-05       Impact factor: 11.025

8.  Defective regulation of energy metabolism in mdx-mouse skeletal muscles.

Authors:  P C Even; A Decrouy; A Chinet
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

9.  Inhibition of α-ketoglutarate-and pyruvate dehydrogenase complexes in E. coli by a glutathione S-transferase containing a pathological length poly-Q domain: A possible role of energy deficit in neurological diseases associated with poly-Q expansions?

Authors:  A J Cooper; K F Sheu; J R Burke; O Onodera; W J Strittmatter; A D Roses; J P Blass
Journal:  Age (Omaha)       Date:  1998-01

Review 10.  What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy?

Authors:  J Vion-Dury; D J Meyerhoff; P J Cozzone; M W Weiner
Journal:  J Neurol       Date:  1994-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.